Compare Eli Lilly And Co (LLY) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs McCormick & Company, Incorporated — how do they compare? Eli Lilly And Co trades at $1,222.61 (market cap $1.08T), while McCormick & Company, Incorporated trades at $53.02 (market cap $14.22B). The key difference: Eli Lilly And Co is far larger — about 75.9× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| LLY | MKC | |
|---|---|---|
Market Cap | $1.08T | $14.22B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $72.26 |
52-Week Low | $639.43 | $45.60 |
Enterprise Value | $1.13T | $18.82B |
Dividend Yield | 0.57% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
McCormick & Company (MKC) trades at $53.10, down slightly by 0.06% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion Unilever Foods merger planned for 2027, driving positive sentiment and a consensus price target of $59.67.
MKC presents a compelling investment case with undervalued metrics and strategic growth from the Unilever deal, though risks include integration challenges and soft consumer volumes. Analysts are mixed but lean bullish, with 36.67% buy ratings. The stock offers a solid dividend and upside potential, but investors should monitor merger execution and volume trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
